香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 Sihuan Pharmaceutical Holdings Group Ltd. 四環醫藥控股集團有限公司 四 環 醫 藥 控 股 集 團 有 限 公 司（「本公司」或「四環醫藥」，連 同 其 附 屬 公 司，統 稱 為「本集團」）董 事 會（「董事會」）欣 然 宣 佈，根 據 恒 生 指 數 有 限 公 司 於2026年2月 13日公佈的截至2025年12月31日 止 期 間 之 恒 生 指 數 系 列 季 度 檢 討 結 果，本 集 團 旗 下 非 全 資 附 屬 公 司 軒 竹 生 物 科 技 股 份 有 限 公 司（「軒竹生物」，於 二 零 二 五 年 十 月 十 五 日 在 香 港 聯 合 交 易 所 有 限 公 司（「香港聯交所」）主 板 上 市，股 份 代 號： 2575）被 納 入 恒 生 綜 合 指 數 之 成 分 股，該 調 ...

Core Viewpoint - The company anticipates a revenue of no less than RMB 2.5 billion for the year, representing a growth rate of over 30% compared to the same period last year, along with a net profit of no less than RMB 150 million [1] Group 1: Business Performance - The aesthetic medicine segment is expected to achieve revenue exceeding RMB 1.4 billion and a segment profit of over RMB 700 million, with both revenue and profit growth rates exceeding 90% year-on-year, becoming the largest revenue and profit contributor for the company [1] - The innovative drug business is entering a harvest phase, with combined revenue from XuanZhu Bio and HuiSheng Bio significantly increasing compared to the previous year, and the commercialization of new products progressing smoothly, indicating a transition from investment to profitability for this segment [1] Group 2: Financial Health - The company maintains a robust financial position with ample cash reserves, having implemented multiple rounds of share buybacks and successfully completed the spin-off listing of XuanZhu Bio, which has led to significant equity appreciation and alleviated R&D funding pressures, thereby optimizing the company's financial structure and driving profit breakthroughs [1]

Summary of the Conference Call for Sihuan Pharmaceutical Company Overview - **Company**: Sihuan Pharmaceutical - **Industry**: Pharmaceutical and Aesthetic Medicine Key Points Financial Performance and Projections - Sihuan Pharmaceutical is expected to turn profitable in 2025, with projected earnings between 150 million to 250 million RMB, reversing previous losses due to R&D investments in innovative drugs and the impact of generic drug procurement [2][5] - The company anticipates entering a product expansion and distribution phase in 2026 and 2027, which is expected to further enhance performance [2][4] - The aesthetic medicine segment is projected to generate nearly 1.4 billion RMB in revenue by 2025, driven by strong sales of the botulinum toxin product, Letibotulinum, expected to reach around 1 billion RMB, and the Sephora Youth Needle, estimated at 200 million RMB [2][6] Product Pipeline and Market Position - Sihuan Pharmaceutical has a robust pipeline in the aesthetic medicine sector with nearly 60 products, showcasing strong R&D capabilities and significant channel advantages [2][4] - Letibotulinum is rapidly penetrating approximately 8,000 aesthetic institutions, with new products like the Youth Needle and Composite Water Light Needle also performing well [2][4] - For 2026, Letibotulinum is expected to maintain a growth rate of over 20%, while new products are projected to achieve sales of 400-500 million RMB [2][6] Innovative Drug Business - The innovative drug segment is expected to significantly reduce losses in 2026, with anticipated annual revenue exceeding 500 million RMB, and a potential break-even point in 2027 [2][7] - Core products such as CDK 4/6 are entering a commercialization acceleration phase, supported by the listing of the subsidiary, Xuanzhu [2][7] Market Valuation and Investment Potential - Current market capitalization of Sihuan Pharmaceutical is 14.1 billion RMB, with earnings forecasts of 710 million and 930 million RMB for 2026 and 2027, respectively, leading to P/E ratios of 19.8 and 15.2 [3][7] - The valuation is considered low relative to growth potential, with a reasonable valuation estimated at 22-25 times P/E, suggesting a target market cap of 21 billion RMB, indicating a potential upside of approximately 50% [3][7] Market Conditions and Strategic Outlook - Recent surveys indicate a stabilization in demand within the aesthetic medicine industry, with some institutions experiencing a shift from declining to positive growth [4] - Improved market liquidity compared to the previous year and increased attention from core institutional investors are expected to bolster the company's market position [5] Additional Insights - The aesthetic medicine segment's revenue for 2025 is expected to be around 1.4 billion RMB, with the generic and innovative drug segments contributing an estimated 1-1.1 billion RMB [6] - The company is poised for significant growth, with a focus on leveraging its product pipeline and market conditions to enhance shareholder value [5][6]

港股市场早盘持续走强，午间收盘，恒生指数涨0.43%，国企指数涨0.41%，恒生科技指数涨1.10%。 黄金股多数走强，灵宝黄金张超7%，山东黄金、中国黄金国际张超5%。 医疗保健持续活跃，时代天使张超6%，映恩生物-B、脑动激光-B、药明生物、四环医药等跟涨。 内地保险板块走弱，中国人寿、中国太保跌超2%。 电影概念陷入回调，大麦娱乐跌超5%，猫眼娱乐跌超4%。 南向资金方面，早盘南向资金净买入超30亿港元。 （文章来源：21世纪经济报道） ...

➢ 美国零售数据疲软；中国将常态化国债 买卖操作。A股窄幅震荡。上证指数收 涨0.13%报4128.37点，录得6连阳；深证 成指涨0.02%，创业板指跌0.37%。光伏 涨幅居前。恒指冲高回落，香港恒生指 数收涨0.58%报27183.15点，恒生科技指 数涨0.62%，恒生中国企业指数涨0.81%。 AI应用股、创新药大涨。大市成交额 2340.4亿港元。外盘方面，欧洲三大股 指收盘涨跌不一，美国三大股指收盘涨 跌不一，道指涨0.1%，标普500指数跌 0.33%报6941.81点，纳指跌0.59%。美国 零售销售意外停滞，市场提高今年降息 押注，关注周三发布的非农就业报告。 中国央行称将常态化开展国债买卖操作。 资料来源：彭博 2026年2月11日星期三 | 27183.15 | 0.58 | 6.06 | | --- | --- | --- | | 9242.75 | 0.81 | 3.69 | | 5451.03 | 0.62 | -1.18 | | 118.25 | -0.39 | -4.22 | | 4128.37 | 0.13 | 4.02 | | 14210.63 | 0.02 | 5.07 ...

2026年2月11日星期三 ➢ 美国零售数据疲软；中国将常态化国债 买卖操作。A股窄幅震荡。上证指数收 涨0.13%报4128.37点，录得6连阳；深证 成指涨0.02%，创业板指跌0.37%。光伏 涨幅居前。恒指冲高回落，香港恒生指 数收涨0.58%报27183.15点，恒生科技指 数涨0.62%，恒生中国企业指数涨0.81%。 AI应用股、创新药大涨。大市成交额 2340.4亿港元。外盘方面，欧洲三大股 指收盘涨跌不一，美国三大股指收盘涨 跌不一，道指涨0.1%，标普500指数跌 0.33%报6941.81点，纳指跌0.59%。美国 零售销售意外停滞，市场提高今年降息 押注，关注周三发布的非农就业报告。 中国央行称将常态化开展国债买卖操作。 183 35 3511-15 XIN YONGAN INTERNATIONAL FINANCIAL HOLDINGS LIMITED Units 3511-15, 35/F, Cosco Tower, Grand Millennium Plaza, www.yafco.com.hk 183 Queen's Road Central, Sheung Wan, Hong ...

Core Viewpoint - The company, Sihuan Pharmaceutical (00460), has announced a positive earnings forecast, expecting revenue of at least 2.5 billion RMB for the year ending December 31, 2025, representing a growth rate of over 30% compared to the previous year [1][5]. Group 1: Financial Performance - The company anticipates a net profit of no less than 150 million RMB for the same period [1][5]. - The growth in performance is primarily driven by the rapid expansion of the medical aesthetics business, which is expected to generate over 1.4 billion RMB in revenue and over 700 million RMB in segment profit, with both metrics showing an annual growth rate exceeding 90% [1][5]. Group 2: Business Segments - The medical aesthetics segment has become the largest contributor to both revenue and profit for the company, significantly boosting overall performance [1][5]. - The innovative drug business is entering a harvest phase, which is expected to improve the company's profit structure [1][5]. Group 3: Financial Health - The company maintains a robust financial position with ample cash reserves, having conducted multiple rounds of share buybacks and completed the spin-off of Xuan Bamboo Biotechnology, which has optimized the financial structure and driven profit breakthroughs [1][5].

四环医药重点推荐3-医美行业需求企稳有拐点，预期带动四环新老产品增长 #医美25年获批3大新品全年业绩转正+26年医美加速创新药大幅减亏业绩3倍增长 行业需求： 1）大趋势有企稳迹象：近期调研华东多地反馈经过22-24年客流、零售价格双重承压下，12-1月客流呈现有好转 的态势，美莱、所调研精品机构均实现双位数客流增长。 2）零售价格鉴于人力、营销成本老品逐渐稳定；3）另外老客户 四环医药重点推荐3-医美行业需求企稳有拐点，预期带动四环新老产品增长 4）肉毒是第二大注射品类，目前行业出货量高单位数-低双位数增长，预计未来多年都有增长动能。 四环现有医美核心产品：1）肉毒素乐提葆；2）斯弗妍童颜针倾妍少女针；3）复合动能素冷妍；4）铂安润玻尿 酸；5）黑曜双波黄金微针。 行业需求： 1）大趋势有企稳迹象：近期调研华东多地反馈经过22-24年客流、零售价格双重承压下，12-1月客流呈现有好转 的态势，美莱、所调研精品机构均实现双位数客流增长。 2）零售价格鉴于人力、营销成本老品逐渐稳定；3）另外老客户消费有升级趋势，客单走高。 品类细分： 1）注射填充类玻尿酸有压力，但童颜针2025年因为更多定位中档的厂家获批出 ...

Market Overview - The Hang Seng Index is expected to be constrained by this year's high of 28,056 points due to the hawkish stance of the newly appointed Federal Reserve Chairman and a rebound in the US dollar index, which has led to profit-taking in the commodity market [2] - The Chinese government is anticipated to focus on expanding domestic demand and technological self-sufficiency in the first quarter of 2026, as it marks the beginning of the 15th Five-Year Plan [2] - There is a policy vacuum in China ahead of the Two Sessions, with many provinces lowering their GDP growth targets, leading to expectations of a GDP growth target of 4.5%-5% for 2026, down from approximately 5% in 2025 [2] Company News - Alphabet is expected to raise $32 billion through a rare issuance of century bonds in GBP [4] - Alibaba has launched the RynnBrain model, which aims to give robots a "thinking brain" [4] - Semiconductor manufacturer SMIC reported a 61% increase in profits last quarter, exceeding revenue guidance [4] - WuXi Biologics has issued a profit warning, expecting a 46% increase in profits for the previous year [4] Economic Outlook - The Federal Reserve maintained interest rates in January, aligning with market expectations, and expressed a positive outlook on economic activity, indicating a cautious approach to future rate adjustments based on economic data [4] - Recent economic data has shown resilience, which may limit the scope for interest rate cuts in the near term [4] - Geopolitical tensions have led to a rebound in oil prices, although an oversupply situation is expected to limit the upward movement of international oil prices [4] Sector Focus - The travel sector is experiencing strong demand as the Lunar New Year approaches [7] - The AI sector is seeing rapid growth due to intensive upgrades in AI models, benefiting the semiconductor industry [7] - The innovative pharmaceutical sector continues to see significant licensing deals and ongoing international expansion [7] Macro Focus - The People's Bank of China is expected to implement a moderately loose monetary policy, utilizing tools such as reserve requirement ratio cuts and interest rate reductions to support economic growth and stabilize prices [8] - The central bank aims to maintain liquidity and financing conditions that align with economic growth and price level expectations [8]

消息面上，四环医药公告，集团预期截至2025年12月31日止年度录得收入不低于25亿元人民币，相较于 去年同期增速逾30%，及不低于1.5亿元人民币的净利润。 四环医药(00460)盈喜后涨超6%，截至发稿，涨2.99%，报1.72港元，成交额5114.13万港元。 业绩增长主要由于集团医美业务实现高速增长，于该年度内实现收入逾14亿元及实现分部利润逾7亿 元，相较于去年收入及分部利润年度增速均超过90%，成为集团第一大收入与利润支柱，带动整体业绩 大幅提升；创新药业务进入收获期，显著改善集团盈利结构；公司财务状况稳健，账面现金充裕，实施 多轮股份回购并完成轩竹生物分拆上市，优化了集团财务结构，推动利润端实现突破。 ...